The pan-cancer methylation product jointly developed by Express Benchmark Medical and Twist Bioscience is launched globally

▎This article is from a benchmark medical press release.
On October 11, 2021, AnchorDx and Twist Bioscience announced that they have jointly developed methylation library preparation and targeted enrichment for pan-cancer species research The NGS sequencing product-TopVest-benchmark methylated pan-cancer detection (hereinafter referred to as "methylated pan-cancer detection product") was launched globally on September 24 (US time)
.

This methylated pan-cancer detection product is a technical achievement jointly developed by Benchmark Medical and Twist in the past two years.
It has the advantages of wider coverage, more accurate data analysis, and higher detection efficiency.
It combines the long-term independent accumulation of large samples of benchmark medical The proven advantages of pan-cancer biomarkers, as well as Twist's technical advantages and quality control advantages in probe design, DNA synthesis, can ensure stable and uniform high performance in large-scale screening applications
.

The product covers 47 TCGA (The Cancer Genome Atlas) disease types, including 31 types of cancers such as lung cancer, breast cancer, and colorectal cancer.
It can be used to study tumor biology such as the occurrence, development and metastasis of a variety of cancers.
The related gene regulation process (methylation level) can also provide efficient and reliable R&D tools for the development of early cancer screening, early diagnosis, prognosis, and recurrence monitoring products for genetic testing companies
.

Dr.
Emily Leproust, CEO and co-founder of Twist, said: “DNA methylation has become an increasingly important biomarker for early cancer detection
.

However, methylation is caused by low sensitivity, low detection efficiency, and high cost.
Detection is challenging
.

We have developed a unique methylation enrichment method that breaks through this technical bottleneck and shows superior methylation detection performance
.

Twist cooperated with the benchmark medical company in the early detection of cancer, using the professional accumulation and experience of the benchmark medical in the cancer field, developed the TopVest-benchmark methylated pan-cancer detection technology to support more diversified products and technologies The launch of the platform
.

We are very happy to bring pan-cancer methylation detection to the scientific community
.

"▲ Dr.
Jianbing Fan, Founder and CEO of Benchmark Healthcare Related Reading: After 5 years of persistence, precision medicine will enter the homes of ordinary people: An interview with Benchmark Healthcare, Dr.
Jianbing Fan, Chief Executive Officer and Founder of Benchmark Healthcare, Dr.
Jianbing Fan, said: “This benchmark The TopVest-benchmark methylation pan-cancer detection product jointly developed by medical and Twist is a high-performance and cost-effective pan-cancer DNA methylation research tool, which will promote basic scientific research in the scientific and business circles And the development of diagnostic technology and products
.

We hope to empower researchers around the world and provide a higher level of basic research and development platform, so as to facilitate the birth of more advanced cancer detection technologies and products that benefit mankind
.

"Reference material: [1] The pan-cancer methylation product jointly developed by Benchmark Medical and Twist Bioscience is launched globally.
Retrieved October 11, 2021, from https:// Statement: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.

This article is for information exchange purposes only.
The views
in the
article do not represent WuXi AppTec's position, nor do they support or oppose WuXi AppTec's views in the article .
This article is not a treatment plan.
Recommended
.

If you need guidance on the treatment plan, please go to a regular hospital for treatment
.